“Innovations DivisionThe Innovation Division continues to be primarily focused on its flagship project, being the commercialisation of the Sr-HT-Gahnite Cervical Spinal Cage. This project continues to see positive results. Allegra remains on track to submit this project for regulatory 510k approval with the US Federal Drug Administration (FDA) on or around 31st March 2023.”
- Forums
- ASX - By Stock
- AMT
- Ann: Company Update Correction
Ann: Company Update Correction, page-2
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AMT (ASX) to my watchlist
|
|||||
Last
2.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.468M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AMT (ASX) Chart |
Day chart unavailable
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online